


o o o o v e s c o
innovation in scope

one & done

OTSC[®] – The first choice: highest efficacy in GI bleeding.



Proven clinical benefit*
www.ovesco.com



OTSC[®]
SYSTEM



Proven clinical benefit:

OTSC® in first-line therapy significantly reduces re-bleeding risk and bleeding associated mortality in UGIB (FLETRock evaluation¹).

Compared to Rockall's validated prediction, re-bleeding risk and bleeding related mortality were significantly reduced from 53.2 % to 21.4 % ($p < 0.001$) and 27.9 % to 10.9 % ($p = 0.011$), respectively in high-risk Rockall score (score 8) patients treated with the OTSC.

OTSC® significantly improves outcome of hemostasis in patients randomized to OTSC® or standard therapy (STING trial²).

Successful hemostasis was achieved in 96.8 % vs 62.5 % ($p = 0.002$) of otherwise unsuccessfully treated patients, now receiving either OTSC or injection plus other clips or thermal coagulation.

1 Wedi E. et al. (2017), **FLETRock analysis: OTSC in first-line therapy reduces re-bleeding risk and bleeding associated mortality in UGIB: multicenter data evaluation.** 47th DGE-BV Congress, Berlin, Germany, April 6 - 8, 2017.

2 Schmidt A. et al. (2017), **Over-the-scope-clips versus standard endoscopic therapy in patients with recurrent peptic ulcer bleeding – a prospective randomized, multicenter trial (STING).** Digestive Disease Week®, Chicago, IL, May 6 - 9, 2017.



Download link to the symposium presentations at DGE-BV 2017.
Further information available at www.ovesco.com